Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-FORCE-1: RRx-001 with Radiation and Temozolomide in Glioblastoma
NCT02871843Phase 1Completed
- Sponsor
- EpicentRx
- Start
- Feb 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nibrozetone in glioblastoma (GBM) and anaplastic glioma, sponsored by EpicentRx. Primary endpoint: Number, frequency and type of adverse events at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
Nibrozetone
03
Conditions
glioblastoma (GBM)anaplastic glioma
Beyond the preview
Go deeper on NCT02871843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871843.